VLA1601 Zika Vaccine Description
Valneva SE's VLA1601 is a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide.
Valneva currently has this vaccine development program on hold, as cases of Zika have significantly declined since 2016.
France-based Valneva is a specialty vaccine company focused on preventing diseases with major unmet needs. The Company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva’s portfolio also includes two commercial vaccines for travelers.
VLA1601 Zika Vaccine Indication
VLA1601 is a vaccine candidate indicated to prevent Zika infection. Since 1952, Zika outbreaks have been reported in tropical Africa, Southeast Asia, the Pacific Islands, and the Americas in 2015.
According to the WHO, there is scientific consensus that the Zika virus (ZIKV) is a cause of microcephaly and Guillain-Barré syndrome, says the company.
VLA1601 Zika Vaccine Dosage
VLA1601 is administered intramuscularly in the deltoid muscle.
Each dose is administered intramuscularly in the deltoid muscle on Days 0 and 28. Also, an accelerated 2-dose vaccination schedule on Days 0 and 7 will be assessed for both doses.
VLA1601 Zika Vaccine Clinical Trial
Valneva has concluded the Phase 1 trial, and the results obtained will allow the Company to design a Phase 2 trial if it chooses to continue this program.